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Rapamycin extends lifespan and attenuates age-related pathologies in mice when
administered through diet at 14 parts per million (PPM). Recently, we reported that
daily intraperitoneal injection of rapamycin at 8mg/kg attenuates mitochondrial disease
symptoms and progression in the Ndufs4 knockout mouse model of Leigh Syndrome.
Although rapamycin is a widely used pharmaceutical agent dosage has not been
rigorously examined and no dose-response profile has been established. Given these
observations we sought to determine if increased doses of oral rapamycin would
result in more robust impact on mTOR driven parameters. To test this hypothesis,
we compared the effects of dietary rapamycin at doses ranging from 14 to 378
PPM on developmental weight in control and Ndufs4 knockout mice and on health
and survival in the Ndufs4 knockout model. High dose rapamycin was well tolerated,
dramatically reduced weight gain during development, and overcame gender differences.
The highest oral dose, approximately 27-times the dose shown to extendmurine lifespan,
increased survival in Ndufs4 knockout mice similarly to daily rapamycin injection without
observable adverse effects. These findings have broad implications for the effective use
of rapamycin in murine studies and for the translational potential of rapamycin in the
treatment of mitochondrial disease. This data, further supported by a comparison of
available literature, suggests that 14 PPM dietary rapamycin is a sub-optimal dose for
targeting mTOR systemically in mice. Our findings suggest that the role of mTOR in
mammalian biology may be broadly underestimated when determined through treatment
with rapamycin at commonly used doses.
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Introduction
Rapamycin, a specific inhibitor of the mechanistic Target
Of Rapamycin (mTOR), was the first pharmacological agent
reproducibly demonstrated to extend lifespan in multiple
organisms including budding yeast, nematodes, flies, and mice
(Harrison et al., 2009; Ha and Huh, 2011; Partridge et al.,
2011; Choi et al., 2013; Johnson et al., 2013a,b). Rapamycin was
first demonstrated to increase murine lifespan by the National
Institute on Aging (NIA) Interventions Testing Program (ITP)
in a study where genetically heterogeneous UMHET3 mice
were fed a diet supplemented with 14 PPM rapamycin in a
microencapsulated formula beginning at around 600 days of
age (Harrison et al., 2009). This diet was subsequently shown
to extend lifespan in UMHET3 mice treated from a young age
(Miller et al., 2011) and C57Bl/6 inbred mice when initiated
at either 19 months of age (Zhang et al., 2014) or mixed ages
(Neff et al., 2013). Surprisingly, dietary treatment with rapamycin
at 14 PPM had comparable effects on survival whether treatment
was initiated in young or middle-aged animals. Similar to dietary
delivery, an intermittent treatment protocol where 1.5mg/kg
rapamycin was injected subcutaneously three times per week,
2 weeks out of every month, was shown to extend lifespan in
the 129/Sv background starting in young animals (Anisimov
et al., 2011). In addition to increasing lifespan, there is a general
consensus that rapamycin attenuates age-associated declines in
some measures of cardiac, immune, muscular, and cognitive
function, increasing overall healthspan (Spong and Bartke, 2012;
Wilkinson et al., 2012; Blagosklonny, 2013; Kaeberlein, 2013; Neff
et al., 2013; Zhang et al., 2014). mTOR inhibition by rapamycin
has also been shown to provide benefit in models of disease such
as the murine model of Leigh Syndrome.
Leigh Syndrome (LS) is a severe mitochondrial disease
that occurs in about 1:40,000 newborns and is associated
with retarded growth, muscular deficits including myopathy
and dyspnea, lactic acidosis, and a characteristic progressive
necrotizing encephalopathy of the vestibular nuclei, cerebellum,
and olfactory bulb (Budde et al., 2002, 2003; Anderson
et al., 2008). Ndufs4 encodes a subunit of Complex I of
the mitochondrial electron transport chain; mutations in the
NDUFS4 gene cause LS in humans (Budde et al., 2000, 2003;
Darin et al., 2001; Anderson et al., 2008; Quintana et al., 2010),
and the Ndufs4 knockout (KO) mouse is a murine model of LS
(Kruse et al., 2008; Quintana et al., 2010). Ndufs4 KO mice have
decreased Complex I levels and activity in multiple tissues and
show severe and progressive symptoms of mitochondrial disease
that mirror human LS. LS results in death at an average of 6–7
years in humans, and Ndufs4 KO mice show a similar early-life
mortality with an average lifespan of just 50 days.
In a recently published study, we reported a striking
suppression of Leigh Syndrome phenotypes by rapamycin in
Ndufs4KO animals (Johnson et al., 2013c). 8mg/kg of rapamycin
increased survival by roughly 30% when administered every
other day via intraperitoneal injection (IP) and more than
doubled median survival and tripled maximum survival when
administered every day. In addition to the robust effect on
survival, daily injection of rapamycin also attenuated multiple
aspects of disease including neuroinflammation, weight loss,
and behavioral phenotypes associated with neurological decline.
Given these findings, we sought to determine whether oral
delivery of encapsulated rapamycin could achieve effects similar
to daily IP injection in regards to developmental weight gain
in wildtype mice and disease in Ndufs4 KO animals. Here, we
report that oral delivery of encapsulated rapamycin has dose-
dependent effects on developmental weight in mice and disease
onset and progression in the murine model of LS. A dosage
of 378 PPM, approximately 27-fold higher than that shown to
extend lifespan of WT animals, was necessary to achieve effects
on survival and body composition in control and Ndufs4 KO
animals comparable to daily IP injection of 8mg/kg rapamycin.
Importantly, although these high-doses of rapamycin resulted
in a dramatic reduction in animal size, reminiscent of pituitary
dwarfism, we observed no detrimental effects in treated mice.
These studies have major implications for experimental and
clinical use of rapamycin.
Materials and Methods
Animals
Heterozygous Ndufs4 knockout mice on a C57Bl/6NIA
background were bred to produce homozygous KO animals.
Injectable rapamycin preparation and delivery and animal
care and end-of-life criteria were as previously described
(Johnson et al., 2013c). All animal use was in accordance with
the University of Washington institutional guidelines and
experiments were performed as approved by the Institutional
Animal Care and Use Committee. Ndufs4 heterozygous mice
and wild-type mice are phenotypically indistinguishable in all
studies (both here and previously published) and are pooled as
controls for the experiments described. All mice used in these
studies were C57Bl/6NIA animals.
Encapsulated rapamycin was obtained from the Barshop
Institute at the University of Texas Health Science Center at San
Antonio and Rapamycin Holdings, Inc. Standard mouse chow
was ground to a powder and mixed with encapsulated rapamycin
at 14, 42, 126, or 378 PPM. 300mL of 1% agar melted in sterile
water was added per kilogram of powdered chow and themixture
was pelleted and baked at 55◦C for 2–3 h to harden. Pellets were
then vacuum-sealed for short-term (4◦C) or long-term (−20◦C)
storage. Control food contained either no drug or encapsulation
material (eudragit) alone at a concentration matching that in the
rapamycin chow, as indicated.
Mice began receiving assigned diet treatments upon weaning,
at 20–21 days of age. Mice assigned to rapamycin (8mg/kg) or
vehicle injection groups began treatments at post-natal day 10
(P10) as previously described (Johnson et al., 2013c).
Rapamycin Blood Level Analysis
Whole-blood samples were collected in EDTA tubes by cardiac
puncture immediately following euthanasia. All blood samples
were collected at approximately the same time of day, during
light cycle, tominimize variation between samples due to feeding.
Samples were frozen and shipped on dry ice to the Javors
laboratory in the Department of Psychiatry at the University
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of Texas Health Science Center San Antonio for analysis by
HPLC-MS.
Statistical Analysis
Linear regression and related statistics in Figure 1A were
generated in GraphPad Prism using data for 14, 42, and 126
PPM rapamycin with y-intercept was set to 0. Survival curves
were compared by Log-rank test in GraphPad. Pairwise t-tests
were performed in Excel. All tests were two-tailed and assumed
equality of variance, with a p-value less than 0.05 considered
statistically significant.
Results
Dietary Rapamycin Reduces Developmental
Weight in a Dose-dependent Manner
To assess the efficacy and effects of high-dose dietary rapamycin,
control and Ndfus4 KO animals were fed chow containing 42,
126, or 378 PPM rapamycin beginning at weaning (∼P20, see
Materials and Methods). Circulating levels of rapamycin were
measured after at least 7 days on the rapamycin diet (Figure 1).
Levels of circulating rapamycin increased in a linear manner
from 14 to 126 PPM at a rate of approximately 3.2 ng/ml serum
rapamycin per PPM dietary rapamycin increase, with linearity
decaying between 126 and 378 PPM.
Dietary rapamycin reduced developmental weight gain in a
dose-dependent manner in control animals, with strength of
effect ranging from no observed impact at 14 PPM (data not
shown), to a robust and highly significant reduction in body size
at 378 PPM that is similar in magnitude to what we previously
reported for daily injection of 8mg/kg (Figure 2). Rate of weight
gain during 25–30 days of life was decreased in a dose-dependent
manner. Mice treated with the highest doses of rapamycin are
approximately 50% the size of control littermates at 30 and
60 days of age, reminiscent of genetic interventions in growth
signaling such as the long-lived Snell and Ames dwarf mice
(Cheng et al., 1983). While gender specific effects of rapamycin
at low doses are well established, we found that at 378 PPM
rapamycin male and female animals have indistinguishable rates
of weight increase. Although a robust decrease in developmental
weight gain occurred in both genders by 378 PPM, it should be
noted that this may not be the level of maximum possible effect
as we did not examine higher doses.
Dietary Rapamycin Increases Ndufs4 Knockout
Survival in a Dose-dependent Manner
We next assessed the impact of dietary rapamycin on Ndufs4 KO
animals fed a diet containing 42, 126, or 378 PPM rapamycin
beginning at weaning. As previously shown, control treated
Ndufs4 KO mice show a slightly reduced developmental weight
gain compared to control animals until 35 days of age where
disease symptoms onset. This is followed by a progressive
decline in body weight concomitant with the presentation of
neurological symptoms and a steady loss of fat mass (Johnson
et al., 2013c). We found that dietary rapamycin treatment altered
weight profiles of Ndufs4 KO animals in a dosage dependent
manner similar to the effects in wildtype animals (Figure 3).
14 PPM dietary rapamycin had no impact on disease onset or
progression (data not shown). 42 PPMdietary rapamycin delayed
the rapid decline in weight roughly proportionally to the increase
in survival for this cohort (Figures 3C,D), while mice treated
with 126 PPM or 378 PPM showed a reduced rate of weight gain
but were largely protected against the rapid weight loss occurring
around P35 in control animals, showing similar weight profiles
FIGURE 1 | Blood levels of rapamycin resulting from dietary and IP
injection delivery. Blood levels of rapamycin in mice treated with dietary
rapamycin or intraperitoneal injection as indicated. Dietary concentration to
blood level relationship shown in inlayed graph; linear regression generated
using 14, 42, and 126 PPM data with 95% confidence intervals, correlation
co-efficient, and correlation p-value indicated. All error bars represent SEM.
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FIGURE 2 | Rapamycin reduces developmental weight gain in a
dose-dependent manner. Control male (A,B) and female (C,D) mice
treated with dietary rapamycin from weaning (approximately post-natal day
21). Rate calculated from post-natal day 25–30 was reduced in a
dose-dependent manner in both genders. Eudragit (encapsulation material)
alone at a quantity equivalent to that in 378 PPM rapamycin chow had no
impact on developmental weight gain. Male and female mice treated with
378 PPM dietary rapamycin show similar weight curves and developmental
weight gain rates. Rapamycin injection—8mg/kg/day IP injection. Error bars
represent SEM. **p < 0.005; n.s., not significant.
to Ndufs4 KO animals treated with 8mg/kg/day of rapamycin by
IP injection. These observations are consistent with the effects
of daily IP injection of 8mg/kg rapamycin beginning around
weaning and demonstrate that high doses of dietary rapamycin
are well tolerated and are required in order to achieve robust
benefits from the drug in this disease model.
A comparison of the effects of dietary rapamycin and daily
rapamycin injection on median lifespan, maximum lifespan,
and rate of developmental weight gain reveals that 378 PPM
impacts developmental weight gain roughly equivalently to daily
IP rapamycin at 8mg/kg but may appear not to be sufficient to
achieve the same benefits in regards to lifespan in the Ndufs4 KO
animals (Figure 3D, see discussion).
Rapamycin Treatment Starting at P35 Delays
Mortality Without Impacting Developmental
Weight Gain in the Ndufs4 −/− Mice
As most cases of severe mitochondrial disease in children
are diagnosed after the presentation of symptoms, we sought
to determine if rapamycin can have a beneficial impact
on mitochondrial disease when initiated after the onset of
neurological symptoms. To address this we treated a group of
knockout animals with 378 PPM dietary rapamycin starting at
P35, the age at which weight peaks in the Ndufs4 knockout mice
and neurological phenotypes become apparent. Animals in this
cohort showed a significant delay inmortality relative to controls,
although the rescue was not as robust as that of 378 PPM started
at weaning (Figure 4). These data indicate that the benefits of
rapamycin are at least partly independent of any effects the drug
may have on very early developmental weight, but that earlier
treatment provides the greatest benefit.
New Insight Into the Impact of Rapamycin on
Aging and Disease
While the beneficial effects of mTOR inhibition by rapamycin
on aging and age-related disease have been reproducibly
demonstrated, there has been recent debate over whether the
anti-cancer effects of rapamycin may account for the lifespan
benefits in the mouse model. Notably, a 2013 paper published
by Neff et al. (2013) suggested that the effects of rapamycin
on murine lifespan are completely explained by the anti-
cancer effects of the drugs, rather than an effect on the aging
process. Given our findings that dietary rapamycin at 14 PPM
is at the low end of the dose-response curve for each of the
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FIGURE 3 | High-dose dietary rapamycin attenuates disease and
enhances survival in Ndufs4 −/− mice. Dietary rapamycin reduces
developmental weight gain and attenuates the progressive weight loss
phenotype in a dose-dependent manner (A,B). Dietary rapamycin improves
survival in a dose-dependent manner (C). The effect of 378 PPM dietary
rapamycin on weight is slightly greater than daily IP rapamycin injection while
IP injection resulted in a greater increase in median and maximum survival
(D). The oldest mouse in the 378 PPM group was euthanized due to lack of
chow and was still healthy by gross observation at the time of euthanasia.
Rapamycin injection—8mg/kg/day IP injection. Error bars represent SEM.
**p < 0.005. 378, but not 42, PPM treatment significantly increased survival
by Log-rank test (p = 0.086 and 0.006 for 42 and 378 PPM, respectively; IP
injection shown for reference, previously reported elsewhere) (Johnson et al.,
2013b).
phenotypes described here, we decided to examine relationships
between treatment dose, serum levels, and phenotypic outcome
in published studies that utilize this drug in an attempt to explain
the somewhat discordant results in the rapamycin literature
(Figure 5, Table 1). An examination of studies involving dietary
rapamycin use indicates that the blood levels of rapamycin
we observed in our mice are consistent with those reported
in other studies using 14 and 42 PPM (Figure 5A). A closer
inspection of the 14 PPM dose data reveals that the initial 2009
ITP publication of lifespan extension using microencapsulated
rapamycin resulted in higher than average blood serum levels of
the drug, while the 2013 Neff et al. paper fell at the far low end
of the distribution by blood level (Figure 5B). Critically, there
is a greater than 10-fold difference in reported blood levels of
rapamycin when comparing the 2009 ITP study and the 2013
Neff et al. study, a difference that may largely account for any
differences in outcome reported by these groups.
Discussion
Here we present a dose-response profile for dietary rapamycin
in a mouse model. Our observations indicate that the commonly
used 14 PPM dose is significantly lower than necessary to observe
robust effects on developmental weight gain and attenuate
disease in the Ndufs4 KO mouse model of Leigh Syndrome.
This data demonstrate that dietary rapamycin at doses much
higher than previously tested in normative aging are not only well
tolerated, but are also necessary to significantly impact multiple
physiological outcomes, raising the possibility that doses higher
than 14 PPM may have a more robust impact on longevity and
healthspan in normal aging. The standard dose of 14 PPM is at
the threshold of detectable effects, indicating it may be at the
border of clinical significance. Suboptimal dosing may explain
the results of studies that failed to observe significant effects of
14 PPM rapamycin on some parameters of aging (Neff et al.,
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FIGURE 4 | Impact of high-dose dietary rapamycin on Ndufs4 −/−
mice when initiated at P35. (A) High-dose rapamycin provides some
benefit to survival when initiated at P35 without impacting developmental
weight (B). Control animals in (A) only include those surviving past P35.
Survival of mice treated starting at P35 is significantly greater than control
treated animals (p = 0.0002, Log-rank test).
FIGURE 5 | A comparison of rapamycin blood levels in studies using
dietary rapamycin treatment. (A) Blood levels of rapamycin reported in
studies using dietary treatment (black datapoints) and in our study (colored
datapoints). (B) A comparison of reported blood levels in studies using 14
PPM dietary rapamycin with the initial ITP report (Harrison et al.) and the 2013
report suggesting few benefits to aging parameters (Neff et al.) indicated. Bar
and whiskers represent median and interquartile range of published blood
levels for 14 PPM rapamycin. Reported limit of detection by HPLC indicated
by dashed line.
2013). Rapamycin may be effective in cancer inhibition at doses
lower than that necessary for robust inhibition of normal mTOR
signaling, and rapamycin diet at the standard ITP dose of 14 PPM
may have robust anti-cancer effects with only a relatively modest
influence on other age-related pathologies. We suspect that the
high doses tested here are likely to provide more potent longevity
and healthspan promoting effect than previously reported.
Maintaining high levels of circulating rapamycin also appears
necessary to significantly attenuate mitochondrial dysfunction.
We previously found that every-other-day injection of 8mg/kg
rapamycin results in only a modest attenuation of disease in
the Ndufs4 KO model while daily injection provides a strong
positive effect. A similar response was also seen in the Lmna
KO mouse model (Ramos et al., 2012). High-dose injection
provided the greatest benefit to survival in the Ndufs4 KO
model while oral rapamycin at 378 PPM had the strongest
impact on developmental weight gain (Figures 3C,D); the bolus
provided by injection provides an enhanced benefit over steady
dietary delivery in the mitochondrial disease model, perhaps by
overcoming blood-brain barrier. Daily IP injection of rapamycin
at 8mg/kg alters neural activity associated with aging (Yang et al.,
2012) and robustly reduces whole brain levels of phospho-s6,
an indicator of mTOR activity, in Ndufs4 KO and WT animals
(Johnson et al., 2013c). While the importance of mTOR signaling
in brain vs. peripheral tissues in aging and Leigh syndrome is
not yet known, these reports demonstrate that circulating levels
of rapamycin achieved by daily IP injection are sufficient to
reduce mTOR signaling in the central nervous system. Effective
inhibition of mTOR in the brain may be necessary for the full
benefits of rapamycin in both Ndufs4 KO mice and in normative
aging.
It is worth noting that the use of high dose dietary rapamycin
in long-term intervention studies in mice will be restricted by
cost, as it is currently only available from a single supplier and
this dose is greater than 1000 times more expensive than delivery
by injection. 378 PPM dietary rapamycin (378 ug rapamycin
per gram-food) is 27 times the dose used by the ITP, while
IP injection requires only 8 ug un-encapsulated rapamycin per
gram-mouse weight to achieve comparable circulating levels.
Alternative methods for delivery of oral rapamycin in mouse
chow or the development of stable rapalogs will greatly accelerate
efforts to study the effects of high-dose rapamycin in long-term
treatment paradigms.
We recognize that the use of high-dose rapamycin raises
additional concerns regarding potential side effects. It is
important to note that we observed beneficial effects of
rapamycin in the mitochondrial disease model when initiated
after developmental weight gain—this indicates that the effects
of rapamycin treatment on disease in this setting can be at
least partially uncoupled from the off-target effects on weight.
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TABLE 1 | A comparison of published studies utilizing dietary encapsulated rapamycin.
Dose Blood levels Strain Primary outcome Study
4.7, 14, 42 PPM Female: 7, 16, 80 ng/ml
Male: 6, 9, 23 ng/ml
UM-HET3 Aging Miller et al., 2014
14 PPM Female: ∼5 ng/ml
Male: ∼3 ng/ml
C57Bl/6J and
C57Bl/6NIA
Aging Fok et al., 2014
14 PPM 3–5 ng/ml C57Bl/6NIA Aging Zhang et al., 2014
14, 42 PPM 37, 170 ng/ml ApcMIN Cancer Hasty et al., 2014
14 PPM 10–12 ng/ml TrJ Nerve mylenation Nicks et al., 2014
14 PPM Females: 3.9 ng/ml
Males: 3. 8 ng/ml
Rb1+/− Cancer Livi et al., 2013
14 PPM 4.57 ng/ml (n = 3 mice) C57Bl/6J Cancer Neff et al., 2013
4.7, 14, and
42 PPM
6.5, 13.4, and
57.5 ng/ml
UM-HET3 Aging Wilkinson et al., 2012
14 PPM 60–70ng/ml UM-HET3 Aging Harrison et al., 2009
Oral
nanoparticles
>3000 ng/ml, no
toxicity observed
CD1 Cancer Bisht et al., 2008
14, 42, 126,
and 378 PPM
13, 125, 402,
710 ng/ml
C57Bl/6NIA Developmental weight, disease Data here
The original publication demonstrating murine lifespan extension by microencapsulated rapamycin in bold. Bisht et al., study provided for reference as the highest level of rapamycin
reported in mice and no overt toxicity was observed. UM-HET3—genetically heterogenous mice produced from a four-way cross. C57Bl/6 substrain (National Institute on Aging, NIA,
vs. Jackson laboratory, J) as indicated.
Conversely, in the setting of a disease with 100% mortality early
in life this off-target effect may be seen as tolerable. This will be an
important consideration if rapamycin is brought to clinical trials
for Leigh Syndrome.
Even at the ITP dosage of 14 PPM, sustained periods of
treatment may result in abnormal insulin and glucose responses
reminiscent of diabetes (Lamming et al., 2012). However, while
mice treated chronically with rapamycin show abnormalities in
the context of a glucose tolerance test, this does not equate to a
pathogenic state and it remains unclear whether these animals
actually have any deficiency in glucose homeostasis under
physiologically relevant conditions. Intolerance in this assay may
reflect an altered metabolic state wherein metabolism is shifted
away from glucose utilization, a state of “starvation diabetes”
(Blagosklonny, 2011), where animals are not physiologically
primed to deal with a sudden, non-physiological increase in
blood glucose levels.
Consistent with this, unpublished data from our laboratory
indicates that 90 days of IP injection of 8mg/kg rapamycin
in adult mice does not significantly alter circulating glucose
levels in the blood (data not shown). While more work
is needed to define the physiological effects of high-dose
rapamycin and the true relevance of observed metabolic shifts,
our data clearly demonstrate that chronic, very high dose
rapamycin has no overt toxicity in mice, and any abnormal
physiological findings must be considered in the context of
the known benefits of mTOR inhibition in aging or disease
paradigms. Furthermore, while it was demonstrated that a
modest extension of lifespan in female mice can be achieved
in the context of mTORC1 reduction alone, the importance
of mTORC2 in the beneficial effects of rapamyicn remains to
be determined. The relative roles of mTORC1 and mTORC2
may partially explain the dosage-requirements demonstrated by
our work, in addition to the pharmacokinetic properties and
tissue specific effects of rapamycin, and will require further
study.
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